or Try an Advanced Search...

    Technical Analysis for ANIX - Anixa Biosciences, Inc.

    Grade Last Price % Change Price Change
    F 2.22 0.45% 0.01
    ANIX closed up 0.45 percent on Monday, July 1, 2024, on 35 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical ANIX trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness 0.00%
    Inside Day Range Contraction 0.00%
    Below Lower BB Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish 0.45%
    New 52 Week Low Weakness 0.45%
    Stochastic Reached Oversold Weakness 0.45%
    Below Lower BB Weakness 0.45%
    Gapped Down Weakness 0.45%
    Older End-of-Day Signals for ANIX ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 6 hours ago
    60 Minute Opening Range Breakout about 10 hours ago
    Up 3% about 10 hours ago
    Up 2% about 10 hours ago
    Rose Above Lower Bollinger Band about 11 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ANIX Chart by TradingView
    Basic chart:

    Profile

    Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization.
    Classification
    Sector: Healthcare
    Industry: Diagnostics & Research
    Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Emerging Technologies Cancer Treatment Gene Therapy Leukemia Blood Test Amines Chimeric Antigen Receptor Immune Response

    Is ANIX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 24 Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial
    May 28 7 Penny Biotech Stocks to Triple Your Investment
    May 21 Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
    May 9 Anixa expands cancer vaccine collaboration with Cleveland Clinic
    May 8 Anixa Biosciences enters JV with Cleveland Clinic for additional cancer vaccines
    May 8 Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
    May 7 Sidoti Events, LLC's Virtual May Micro-Cap Conference
    May 6 Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja
    Apr 30 Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024
    Apr 18 Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board
    See more ANIX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.13
    52 Week Low 2.145
    Average Volume 89,062
    200-Day Moving Average 3.38
    50-Day Moving Average 2.72
    20-Day Moving Average 2.50
    10-Day Moving Average 2.42
    Average True Range 0.15
    RSI (14) 32.89
    ADX 32.4
    +DI 13.39
    -DI 33.42
    Chandelier Exit (Long, 3 ATRs) 2.32
    Chandelier Exit (Short, 3 ATRs) 2.59
    Upper Bollinger Bands 2.77
    Lower Bollinger Band 2.23
    Percent B (%b) -0.02
    BandWidth 21.46
    MACD Line -0.12
    MACD Signal Line -0.10
    MACD Histogram -0.0204
    Fundamentals Value
    Market Cap 70.37 Million
    Num Shares 31.7 Million
    EPS -0.32
    Price-to-Earnings (P/E) Ratio -6.94
    Price-to-Sales 680.79
    Price-to-Book 5.87
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.34
    Resistance 3 (R3) 2.35 2.31 2.32
    Resistance 2 (R2) 2.31 2.28 2.31 2.31
    Resistance 1 (R1) 2.27 2.26 2.29 2.26 2.31
    Pivot Point 2.23 2.23 2.25 2.23 2.23
    Support 1 (S1) 2.19 2.20 2.21 2.18 2.13
    Support 2 (S2) 2.15 2.18 2.15 2.13
    Support 3 (S3) 2.11 2.15 2.12
    Support 4 (S4) 2.10